Core Viewpoint - The recent board restructuring at Sichuan Hezhong Yaoyigou Co., Ltd. marks a strategic shift towards technology-driven growth and diversified ecosystem development under the leadership of Chen Shunjun, who has taken over as Chairman and continues as General Manager [1][2][3]. Group 1: Leadership Transition - Chen Shunjun's promotion from Vice Chairman to Chairman signals a strategic focus on technology integration and capital operations, moving from "scale expansion" to "ecosystem development" [2][3]. - The previous Chairman, Li Yanfei, will continue to leverage his extensive resources in the pharmaceutical distribution sector to support the company [2]. Group 2: Strategic Developments - Under Chen's leadership, the company is enhancing its industrial ecosystem by integrating smart technology, e-commerce, artificial intelligence, and big data into a "pharmaceutical + technology" dual-drive model [3]. - The company is accelerating capital operations through investments and collaborations in health, traditional Chinese medicine, and supply chain projects, aiming to establish a second growth curve [3]. Group 3: Governance Structure - The new board consists of nine members, including independent directors with diverse backgrounds in finance, law, and marketing, which will enhance compliance and strategic decision-making [4]. - The establishment of a Strategic and Development Committee led by Chen Shunjun emphasizes the company's commitment to both core business and strategic expansion [4]. Group 4: Management Team Dynamics - The management strategy focuses on "pharmaceutical + technology," "platform + ecosystem," and "self-operated + empowered" models, aiming to build a differentiated competitive advantage [5]. - Key management members bring extensive experience in financial control and capital operations, aligning with the company's long-term focus on the pharmaceutical internet sector [5]. Group 5: Future Outlook - The board's capital perspective and the management team's execution capabilities are expected to complement each other, positioning the company for growth and breakthroughs in new market environments [6].

在产业链上游拓展方面，药易购通过OEM/MAH/股权合作/独家经销/并购重组等绑定核心品种定价话语 权，投资布局民族药中成药、特医特膳、医疗设备、合成生物等领域，拟打造大健康黄金爆品，提升供 应链端的价值含量；在产业链中游的服务环节，药易购在数字化医药分销基础上，加大总代品牌推广力 度，同时向上下游技术赋能，如投资助力医药流通企业、医药连锁企业私域信息化建设的药聚力平台， 对下游连锁进行AI新零售体系赋能(协助信息化智能化升级、搭建及运营AI新零售收费会员体系、搭建 慢病管理体系、连锁药店抖品牌运营体系、C端代运营服务体系)等；在产业链下游延伸方面，药易购通 过搭建C端全域触达能力，包括投资赋能连锁药店、自营/加盟连锁药房、投资O2O无人智能药仓、线上 B2C电商、O2O电商等各类形式直接触达C端，增强公司直接服务终端能力，激活沉睡的C端用户，随 着其创新发展与数智化运营质效的持续提升，药易购增长质量和营运规模也在持续提升，进而推动核心 主营业务和创新业务的可持续发展。 践行循环经济理念，引领绿色发展 报告提到，作为国内首家上市的医药产业互联网企业与科技大健康链主，药易购将可持续发展理念融入 公司长期发展战略 ...